IP Library Granted Patent US 8,241,844
Granted Patent B2
US 8,241,844 · App. 12/572,494 · Granted Aug 14, 2012

Methods and compositions for modulating an immune response with immunogenic oligonucleotides

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,241,844
App. No.
12/572,494
Granted
Aug 14, 2012
Kind
B2
Abstract

This document relates to compositions and methods for modulating an immune response. For example, compositions of immunostimulatory CpG oligonucleotides derived from retroviral genomes are provided.

Claims (9)

1. A method for stimulating lymphocyte cytokine production comprising contacting lymphocytes with an isolated nucleic acid consisting of from 20-84 contiguous nucleotides of a mammalian retroviral sequence, wherein said sequence comprises at least one CpG motif, with the proviso that at least one non-thymidine nucleotide 1, 2, or 3 bases immediately 5′ or immediately 3′ to said CpG motif is substituted with thymidine under conditions wherein said cytokine production is enhanced relative to uncontacted lymphocytes: wherein said nucleic acid consists of a sequence selected from the group consisting of SEQ ID NO: 30, 31, 34, 37, 40, 49, 51.

2. The method of claim 1 , wherein said nucleic acid is 20-50 nucleotides in length.

3. The method of claim 1 , wherein said nucleic acid is 24 nucleotides in length.

4. The method of claim 1 , wherein said mammalian retroviral sequence is a HIV genomic sequence.

5. The method of claim 1 , wherein said mammalian retroviral sequence is a SIV genomic sequence.

6. The method of claim 1 , wherein said contacted lymphocytes form primed lymphocytes.

7. The method of claim 1 , wherein said contacting further comprises application of a therapeutic antigen.

8. The method of claim 1 , wherein said stimulation is measured according to a TLR-9 antagonism assay.

9. The method of claim 1 , wherein said cytokine is selected from the group consisting of IL-6, IL-10, IL-12, and TNF-α, or any combination thereof.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 5, 2015
From: ESTATE OF JEFFREY M. CLARK
To: CREATION ONE FORMULATORS, LLC
Reel/Frame 034897/0170 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 5, 2015
From: BIOINFORMATICA, LLC
To: CREATION ONE FORMULATORS, LLC
Reel/Frame 034897/0325 →
NOTICE OF OWNERSHIP DISPUTE Recorded Nov 22, 2010
From: CLARK, RALPH
To: BIOINFORMATICA
Reel/Frame 025411/0544 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 12, 2010
From: BULLA, LEE A., JR.; GRIKO, NATALYA; SUN, JIAN
To: CREATION ONE FORMULATORS, LLC
Reel/Frame 024215/0195 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 8, 2010
From: CLARK, JEFFREY M.
To: CREATION ONE FORMULATORS, LLC
Reel/Frame 024206/0247 →
Continuity (3)
Provisional Application 61234431 · Aug 17, 2009
Provisional Application 61102641 · Oct 3, 2008
Related Publication 20100119556A1 · May 13, 2010